Trial · NCT03741530
Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage
NCT03741530, Not applicable, Completed, Xijing Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage. Trials, record NCT03741530. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03741530
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage
- NCT number
- NCT03741530
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 220 participants, actual
- Lead sponsor
- Xijing Hospital
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Glibenclamide Tablets, Standard management for ICH
- First posted
- 2018-11-15
- Last updated
- 2022-04-08
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of death or major disability | 90 days after the onset | Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death). |
| Secondary | The change in the volume of ICH from the initial to follow-up CT scans | 3 days after onset | |
| Secondary | The change in the volume of PHE from the initial to follow-up CT scans | 3 days after onset | |
| Secondary | The change in the volume of ICH from the initial to follow-up CT scans | 7 days after onset | |
| Secondary | The change in the volume of PHE from the initial to follow-up CT scans | 7 days after onset | |
| Secondary | The proportion of death or major disability | 3 days after onset | Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death). |
| Secondary | National Institute of Health stroke scale | 3 days after onset | The National Institutes of Health Stroke Scale (NIHSS) is used by healthcare providers to evaluate the impairment caused by stroke. The total score of the scale runs from 0 to 42. The higher score is an indicative of more severe impairment. |
| Secondary | Glasgow Coma Scale | 3 days after onset | The Glasgow Coma Scale is a scale for measuring the conscious state of patients with neurological diseases. The total score of the scale runs from 3 (deep coma or death) to 15 (fully awake person). |
| Secondary | Barthel Index | 3 days after onset | The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life. |
| Secondary | The proportion of death or major disability | 7 days after onset | Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death). |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03741530
GET https://conductscience.org/api/trials/v1/NCT03741530/registered